Zai Lab Announces Upcoming Presentations at September Conferences

SHANGHAI, China and SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ: ZLAB), a China and US-based innovative commercial-stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this September. Details of the conferences are as follows:

Citi’s 14th Annual Biotech ConferencePresentation: Thursday, September 5, 2019 at 10:15 a.m. EDTPresenter: Dr. Samantha Du, Founder & Chief Executive Officer, Tao Fu, President & Chief Operating Officer, and Jonathan Wang, Head of Business DevelopmentLocation: Boston, MA

J.P. Morgan China Healthcare CEO-CFO Forum, China BioMed Innovation and Investment ConferenceDate: Friday, September 20, 2019 at 11:30 a.m. CSTPresenter: Billy Cho, Chief Financial OfficerLocation: Suzhou, China

About Zai Lab

Zai Lab (NASDAQ: ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

Contact:

Zai LabBilly Cho, CFO+86 137 6151 2501[email protected]

Media: Ryo Imai / Robert Flamm, Ph.D.Burns McClellan, on behalf of Zai Lab212-213-0006, ext. 315 / 364, [email protected] / [email protected]

Investors: Lee RothBurns McClellan, on behalf of Zai Lab212-213-0006, ext. 331, [email protected]

You May Also Be Interested In

• ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
• Anoto receives first commercial purchase order starting the phased global rollout of LAMY co-branded product
• GHO Capital appoints Olav König as Head of Investor Relations